GMyelofibrosislioblastoma Myelofibrosis is a rare but serious cancer of the bone marrow that disrupts the body’s normal Glioblastomaproduction of multiforme blood cells. (GBM), a type of central nervous system cancer, is the most common and most aggressive form of primary brain cancer. About Myelofibrosis Incidence Cerebrum Lateral Ventricle Globally, more than 241,000 deaths each year Myelofibrosis is a myeloproliferative neoplasm (MPN), a group Hypothalamus result from brain or nervous system cancer, with of blood cancers that derive from blood-forming stem cells. Median Age Pineal Gland GBM being the mostPrimary common myelofibrosis form of theis rare, disease. Two other blood cancers that are also groupedPituitary as MPNs are at Diagnosis affecting approximately essential thrombocythemia and polycythemia vera. 3rd Ventricle Median AgesMedian in the Age United States There are two main types of myelofibrosis:GBM is generally found in the cerebral 65 Cerebellum in Patienthemispheres develops the of the At Diagnosis1 500,000At Death Patient has 4th Ventricle conditionbrain as a but can be 5859 people worldwide6566 Primary no prior Secondary complicationfound of anywhere essential myelofibrosis:Brain Stem history of myelofibrosis: SOURCE: SEER 2013-2017 SOURCE: SEER 2010-2016 thrombocythemia or another MPN in the brain. Spinal Cord polycythemia vera Staging and Survival Rates

The 5-year relative survival rates GBM survival rates by vary depending on the stage age group in the US GlobalSymptoms Incidence and type of brain orRisk nervous Factors system cancer: About one-third of patients with myelofibrosis in its very early The cause of myelofibrosis remains unclear, but more6% than half stages may have no symptoms of the disease. 35.3% North America of patients have a mutation in the Janus Kinase 2 (JAK2) gene. Estimated Europe Asia 20.3% 9% 22% numbers ofSigns annual and symptoms27,000 of myelofibrosis can include: Additional risk factors can include: 32.7% new brain and Central America 64,600 156,200 nervous system cancer cases Africa 29% Weakness 4,900 Bruising or BoneAustralia or 20-44 Age by regionor fatigue bleeding joint pain 17,000 Localized Distant 45-54 Age South Americaeasily 2,300 22,900 Regional Unstaged 55-64 Age SOURCE: GLOBOCAN 2018 SOURCE: SEER 2010-2016 SOURCE: American Cancer Society 2001-2015 Age History of Exposure to certain Night sweats Itching Mild fever thrombocythemia or industrial chemicals or Common Risk Factors Signs polycythemia& Symptoms vera high radiation levels

The signs and symptoms Headache of GBM can vary depending3.5 to on 5.5 the years size and Blurred vision People younger than 55 and with Median location of the tumor in RadiationPrognosis Exposure Family History Some Genetically good prognostic factors can have survival: the brain. The following Balance problems Inherited Syndromes a median survival of 11 years are common symptoms: Weakness on one side of the body Nausea Seizures Memory and/or Treatment OptionsVomiting Drowsiness speech difficulties Being Male Adults Ages 45-65

Treatment approaches for myelofibrosis are determined by age, Treatment Options abnormal blood cell counts, disease Treatment options for GBM vary JAKdepending on aBlood transfusions, Chemotherapy Targeted Radiation Splenectomy Stem cell progression and overall inhibitors androgen therapy or therapy (surgical removal transplant* numberhealth, butof factors—tumor may include: size, position, whetherother anemia treatments of the spleen) it has spread to other regions of the brain and the overall health of the patient. Several types of treatment options may be considered by a health *Typically appropriate for <5% of patients due to risks associated with the procedure professionalIt is important to treatfor people this type with of myelofibrosis cancer, including: to understand theSu rsymptomsgery of their Radiation Therapy Chemotherapy Targeted Therapy disease and to talk to a healthcare professional about appropriate treatment options. © ©2020 2020 Bristol Bristol Myers Myers Squibb Squibb